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Abstract
Background: Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder
associated with ovulatory dysfunction, abdominal obesity, hyperandrogenism, hypertension, and
insulin resistance.
Methods: Our objectives in this study were (1) to estimate sympathetic-adrenal medullary (SAM)
activity by measuring mean systolic blood pressure (MSAP) in rats with estradiol valerate (EV)-
induced PCO; (2) to estimate alpha1a and alpha2a adrenoceptor expression in a brain area thought
to mediate central effects on MSAP regulation and in the adrenal medulla; (3) to assess
hypothalamic-pituitary-adrenal (HPA) axis regulation by measuring adrenocorticotropic hormone
(ACTH) and corticosterone (CORT) levels in response to novel-environment stress; and (4) to
measure abdominal obesity, sex steroids, and insulin sensitivity.
Results:  The PCO rats had significantly higher MSAP than controls, highe r l e v e l s o f  a l p h a 1a
adrenoceptor mRNA in the hypothalamic paraventricular nucleus (PVN), and lower levels of
alpha2a adrenoceptor mRNA in the PVN and adrenal medulla. After exposure to stress, PCO rats
had higher ACTH and CORT levels. Plasma testosterone concentrations were lower in PCO rats,
and no differences in insulin sensitivity or in the weight of intraabdominal fat depots were found.
Conclusion: Thus, rats with EV-induced PCO develop hypertension and increased sympathetic
and HPA-axis activity without reduced insulin sensitivity, obesity, or hyperandrogenism. These
findings may have implications for mechanisms underlying hypertension in PCOS.
Introduction
Polycystic ovary syndrome (PCOS), a heterogeneous
endocrine and metabolic disorder affecting 6% to 10% of
women of reproductive age, is associated with ovulatory
dysfunction, abdominal obesity, hyperandrogenism, and
in many cases hypertension and profound insulin resist-
ance [1]. Several of these factors increase the risk of cardi-
ovascular disease (CVD) in women [2]. The prevalence of
hypertension in women with PCOS is around 40% [3,4].
PCOS is also associated with a higher risk of myocardial
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infarction (relative risk, 7.4) [4] and, in young women, a
compromised cardiovascular profile, independent of
obesity [5]. Women with PCOS also develop a hyperactive
response to stress [6]. The heterogeneity of the disorder
suggests that there are subpopulations within the syn-
drome. Hypertension and insulin resistance are not uni-
formly present, and hypertension may be absent despite
profound insulin resistance and vice versa [7]. It is not
clear whether PCOS increases the risk of CVD independ-
ently of the metabolic syndrome [8].
The abnormalities detected in PCOS have been attributed
to primary defects in the hypothalamic-pituitary-adrenal
(HPA) axis, the ovarian microenvironment, the adrenal
gland, and the insulin/insulin-like growth factor meta-
bolic regulatory system [1]. Hypertension and defects in
insulin action may be related to enhanced sympathetic-
adrenal medullary (SAM) activity [9]. Increased sympa-
thetic nervous system activity may be associated with
enhanced  α-adrenergic responsiveness, contributing to
elevated blood pressure and hypertension [10,11], and
may play a role in PCOS [6,12,13]. If so, the α1a and α2a
adrenoceptor (AR) subtypes are of interest since they are
strongly implicated in cardiovascular control [14,15].
The etiology of PCOS is unknown, likely reflecting multi-
ple pathophysiological mechanisms, and an accepted ani-
mal model of the disease has not been established. A
recent review concluded that multiple models may be
needed, depending on whether the goal is to investigate
ovarian morphology or a particular PCOS-related disor-
der [16]. In both mechanistic and treatment studies, we
and others have used a model in which PCO is induced by
a single intramuscular (i.m.) injection of estradiol valerate
(EV) in 8-week-old rats [17]. The rats cease ovulating and
develop characteristics of human PCOS, including large
cystic follicles in the ovaries and altered concentrations of
luteinizing hormone [17].
Central neuronal activity in norepinephrine (NE) neurons
is increased in rats with EV-induced PCO [18], suggesting
increased central sympathetic outflow. Increased ovarian
sympathetic tone in rats with EV-induced PCO has been
evidenced by elevations in tyrosine hydroxylase activity
and NE concentration, downregulation of the β2 AR, and
increased production of ovarian nerve growth factor, a tar-
get-derived neurotrophin [19-25].
The stress response is largely mediated by the SAM and
HPA axes. Activation of the HPA axis increases the secre-
tion of adrenocorticotropic hormone (ACTH) and leads
to glucocorticoid release from the adrenal cortex. The HPA
axis and intra-adrenal mechanisms involving the adrenal
medulla might also regulate adrenocortical steroidgene-
sis. Furthermore, adrenocortical steroids influence the
development and the function of adrenomedullary chro-
maffin cells and vice versa [26]. Activation of the SAM
axis, however, increases the release of epinephrine and NE
from the adrenal medulla and stimulates the sympathetic
norepinergic nerves, increasing NE secretion.
These two axes form the key efferent links in the "defeat"
(HPA axis) and "defense" (SAM axis) reactions [27,28].
Chronic activation of either axis can lead to stress-related
diseases such as hypertension, diabetes, and obesity
[27,28].
In this study, we investigated SAM-axis activity and HPA-
axis regulation in rats with EV-induced PCO. To estimate
SAM activity, we measured systolic blood pressure and the
expression of α1a- and α2a-AR mRNAs in the hypotha-
lamic paraventricular nucleus (PVN) and adrenal
medulla. To assess HPA-axis regulation, we measured
ACTH and corticosterone (CORT) concentrations in
response to novel-environment stress. We also measured
abdominal obesity, sex steroid levels, and insulin
sensitivity.
Materials and methods
Animals
Eighteen virgin adult cycling Wistar-Kyoto rats (B & K Uni-
versal AB, Sweden) weighing 190 to 210 g were divided
into two groups and housed four to a cage under standard
conditions (21 ± 2°C, 50% to 60% humidity, 12-hour
light/12-hour dark cycle) for at least 1 week before and
throughout the study, with free access to standard chow
and tap water. The study was approved by the Animal Eth-
ics Committee of Göteborg University and performed in
accordance with the NIH "Guide for the Care and Use of
Laboratory Animals."
Hormonal Treatment and Study Procedure
After 1 week of acclimatization, 8-week-old rats (n = 10)
each received an i.m. injection of EV (Riedeldehaen, Ger-
many), 4 mg in 0.2 mL of oil (arachidis oleum, Apoteket
AB, Umeå, Sweden), to induce PCO [17]; this dose
induces persistent estrus and permanent PCO, i.e. no
fresh corpora lutea, regressing old corpora lutea and
atretic follicles [22]. Controls (n = 8) received vehicle
only. Rats were weighed weekly. Mean systolic arterial
pressure (MSAP) and heart rate (HR) were measured 2, 3,
5, and 7 weeks after the injection. Stress tests were carried
out at 6 weeks. Blood samples for measurement of proges-
terone, 17β-estradiol, and testosterone were obtained at
week 7. Euglycemic hyperinsulinemic clamp tests were
performed at 10 to 11 weeks, the time point when PCO
morphology is fully developed[22].Reproductive Biology and Endocrinology 2005, 3:44 http://www.rbej.com/content/3/1/44
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Vaginal Smear
For 10 days before the stress and clamp tests, estrous
cyclicity was monitored by vaginal smears obtained
between 0800 and 1200 hours. The rat estrous cycle
(estrus, diestrus 1, diestrus 2, and proestrus) usually lasts
about 4 days. In controls, the stress and clamp tests were
performed during estrus, and sex hormone levels were
measured during estrus. In PCO rats, all test procedures
were carried out and blood samples collected during
estrus or pseudoestrus as described [19]
Blood Pressure and HR Measurements
Systolic arterial pressure and HR were measured between
0800 and 1200 hours at 2, 3, 5, and 7 weeks after EV injec-
tion with a tail cuff monitor (RTBP Monitor, Harvard
Apparatus, South Natick, MA) with a light-emitting diode
and a photoresistor connected to a dual-channel recorder.
The rats were conscious and placed on a heating pad, and
their tails were warmed with a heating lamp for 10 min-
utes to cause vasodilatation for an optimal signal. MSAP
was calculated from three consecutive stable recordings.
ACTH and CORT Secretion
At 6 weeks, ACTH and CORT responses to novel-environ-
ment stress were assessed as described [29]. All tests
started between 0700 and 0900 h, and care was taken to
keep the rats undisturbed and fed the night before the
experiment. The next morning, each rat was placed in a
novel environment (new test cage, loud background
noise). Blood (60 µL) for measurement of ACTH and
CORT was obtained from a tail vein before and 15, 30, 60,
90, and 120 minutes after exposure to the novel
environment.
Euglycemic Hyperinsulinemic Clamp Test
At 10 to 11 weeks after injection, rats underwent euglyc-
emic hyperinsulinemic clamp tests as described [30].
Anesthesia was induced with thiobutabarbital sodium
(Inactin, 125 mg/kg body weight; RBI, Natick, MA), and
catheters were inserted into the left carotid artery for
blood sampling and into the right jugular vein for glucose
and insulin infusions. Rats were placed on a heating pad
to maintain a constant rectal temperature of 37.0 ± 0.1°C.
After a bolus injection (Actrapid, 100 U/mL, Novo,
Copenhagen, Denmark), insulin was infused at 8 mU/kg
per minute. A 20% glucose solution in physiological
saline was administered to maintain plasma glucose at 7
mM; the infusion rate was guided by glucose measure-
ments in 10-µL blood samples obtained every 5 minutes
until a steady state was achieved (~60 minutes) and then
every 10 minutes. The mean infusion rate was calculated
from values during the last 60 minute. At 0 and 120 min-
utes, 250-µl blood samples were obtained to measure
MSAP 2, 3, 5 and 7 weeks after EV injection Figure 1
MSAP 2, 3, 5 and 7 weeks after EV injection. At both time 
points, MSAP was significantly higher in PCO rats than con-
trols. Values are mean ± SE. **P < 0.01 versus controls (t 
test).
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Expression of α1a and α2a AR mRNA in the hypothalamic par- aventricular nucleus (PVN) and adrenal medulla; values are  normalized to GAPDH expression Figure 2
Expression of α1a and α2a AR mRNA in the hypothalamic par-
aventricular nucleus (PVN) and adrenal medulla; values are 
normalized to GAPDH expression. Expression of α1a AR 
mRNA was upregulated in the PVN. Expression of α2a AR 
mRNA was downregulated in both the PVN and adrenal 
medulla. Values are mean ± SE. *P < 0.05, **P < 0.01 versus 
controls (t test.
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insulin concentration. Less than 1 mL of blood was taken
from each rat.
Tissues
After the clamp test, rats were decapitated, the hypothala-
mus was quickly removed and dissected on dry ice at the
border of -0.8–-3.8 according to rat brain stereotactic
coordinates [31]. Tissue punches centered on PVN were
taken from the sections using an 18 gauge needle, and the
adrenal medullae were dissected and snap frozen in liquid
nitrogen until assay. The parametrial, mesenteric, retro-
peritoneal, and inguinal adipose tissues, one ovary and
muscles of the hind limb (extensor digitorum longus,
soleus, and tibialis anterior) were rapidly dissected by the
same person and weighed.
Ovarian morphology
The ovary was removed, cleaned of adherent connective
fat tissue, and fixed in 4% formaldehyde buffer for at least
24 hours. Thereafter the samples were dehydrated and
imbedded in paraffin. The ovaries were partially longitu-
dinally sectioned (4 µm, every tenth section mounted on
the glass slide) and stained with hematoxylin and eosin.
An experienced pathologist, blinded to grouping analysed
the follicle population under microscope. There was no
intention to quantify the number of growing or atretic fol-
licles but rather to establish whether ovulation with cor-
pora lutea formation had occurred within the given time
frame. According to morphometric (stereological) and
statistical principles there is no need to perform a statisti-
cal analysis in this situation.
Real-Time PCR Analysis
Total RNA from the PVN and adrenal medulla was
extracted with RNeasy Mini kits (Qiagen, Hilden, Ger-
many). First-strand cDNA was synthesized from 1 µg of
total RNA with TaqMan reverse transcription reagents
(Applied Biosystems., Foster City, CA). Each 100 µl RT-
PCR reaction contained 1 µg of total, 1 × TaqMan RT
buffer, 5 mM MgCl2, 2.5 mM random hexamers, 1 mM
dNTP, 0.4 U/ml RNase inhibitor, and 1.25 U/ml Multi-
scribe RT (PE Applied Biosystems, Foster City, CA, USA).
Reverse transcription was carried out in a PTC-200 PCR
system (MJ Research., Boston, MA, USA) at 25°C for 10
min, 48°C for 30 min and 95°C for 5 min. PCR was per-
formed with the ABI Prism 7700 sequence detection sys-
tem and FAM-labeled probes specific for the α1a AR (NM
017191) and α2a AR (rCT57545) (PE Applied Biosystems,
Stockholm, Sweden). Designed primers and a VIC-labeled
probe for GAPDH (NM_031144) were included as inter-
nal standards. cDNA was amplified for one cycle of 50°C
for 2 minutes and 95°C for 10 minutes, followed by 40
cycles of 95°C for 15 seconds and 60°C for 1 minute.
mRNA levels were calculated with the standard curve
method (User Bulletin 2, PE Applied Biosystems) and
adjusted for GAPDH expression.
RIA and ELISA
Blood was collected into potassium EDTA tubes (ACTH),
heparinized microtubes (CORT and insulin), or ordinary
tubes (steroids) and centrifuged immediately at 4°C in a
microcentrifuge. RIA kits were used to measure ACTH
(DSL-2300, Diagnostic Systems Laboratories, Webster,
TX), CORT (RSL125I Corticosterone RIA kit; MP Biomedi-
cals, Costa Mesa, CA), testosterone (DSL-4100, Diagnos-
tic Systems Laboratories), progesterone (DSL-3400,
Diagnostic Systems Laboratories), and estradiol-17β
(double-antibody estradiol procedure, DPC Scandinavia
AB, Mölndal, Sweden). Insulin levels were determined by
ELISA (Merkodia, Uppsala, Sweden).
Table 1: Total Body Weight during the Study Period
Body weight (g)
Week Control group PCO group P
2 188.9 ± 1.6 192.1 ± 0.9 n.s.
3 205.7 ± 1.7 195.8 ± 1.1 0.001*
4 212.6 ± 1.6 203.6 ± 2.6 0.01*
5 214.9 ± 1.8 208.1 ± 2.6 0.05*
6 221.3 ± 2.3 213.0 ± 2.5 0.05*
7 220.8 ± 2.5 215.5 ± 2.8 n.s.
8 221.3 ± 2.3 216.4 ± 2.5 n.s.
9 225.0 ± 2.5 218.6 ± 2.6 n.s.
10 232.9 ± 3.3 228.5 ± 2.8 n.s.
Weight gain (g/week) 4.7 ± 0.2 3.9 ± 0.3 0.05†
Values are mean ± SE. n.s. = not significant.
*Repeated-measures ANOVA.
†t test.Reproductive Biology and Endocrinology 2005, 3:44 http://www.rbej.com/content/3/1/44
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Statistical Analysis
All statistical analyses were performed with SPSS 11.0
software. Body weight and hemodynamic data were ana-
lyzed by repeated-measures ANOVA. Weight gain, tissue
weight, glucose infusion rate and glucose and insulin lev-
els, stress and sex hormones, and mRNA levels were ana-
lyzed by two-tailed t test. Values are expressed as mean ±
SE. P < 0.05 was considered significant.
Results
PCO Rats Develop Hypertension
At 5 and 7 weeks, MSAP was significantly higher in the
PCO group than in controls (Figure 1). At 7 weeks, HR
was also significantly higher in the PCO group (405 ±
13.6 versus 345 ± 10.0 beats/minute, P < 0.001).
Expression of AR mRNA in the Hypothalamic 
Paraventricular Nucleus and Adrenal Medulla
Expression of α1a AR mRNA in the PVN was significantly
higher, and expression of α2a AR mRNA in the PVN and
adrenal medulla significantly lower, in the PCO group
than in controls (Figure 2).
ACTH and CORT Responses to Stress Are Higher in PCO 
Rats
To assess effects of EV exposure on the HPA axis, we meas-
ured the ACTH and CORT responses to novel-environ-
ment stress at 6 weeks (Table 2). At baseline, ACTH levels
were similar in the two groups, while CORT levels tended
higher in PCO rats. At 15 and 30 minutes, ACTH levels
were higher in PCO rats than controls, but the difference
was significant (P < 0.05) only when the two time points
were analyzed together (not shown). At 30 and 60 min-
utes, CORT levels were significantly higher in the PCO
group.
PCO Rats Have Lower Testosterone and Higher 
Progesterone Levels
The PCO group had significantly lower testosterone and
higher progesterone concentrations than the controls
(Table 3). There were no differences in 17β-estradiol
concentrations.
PCO Rats Have Normal Insulin Sensitivity
The glucose infusion rate and plasma insulin and glucose
concentrations before and during the clamp test are
shown in Table 4. Insulin sensitivity was not significantly
different in the PCO and control groups, as reflected by
the glucose infusion rate.
Ovarian morphology – day 60
The ovaries in the control group exhibited a typically nor-
mal appearance with follicles and corpora lutea in differ-
ent stages of development and regression. The ovaries in
the PCO group displayed typical PCO-like changes [17],
and both the number and size of the corpora lutea in these
groups were decreased compared with the control group.
Typically, no young corpora lutea were present in the PCO
groups. The dominant structures were atretic follicles,
regressing old corpora lutea, and a few growing "healthy"
follicles in the primary, secondary, and tertiary stages (Fig-
ures 3).
Table 2: Plasma ACTH and CORT Concentrations before and in Response to Novel Environment Stress Test 6 Weeks after EV 
Injection
Hormone Control group PCO group P
ACTH (pmol/L)
0 min 56.48 ± 5.97 52.21 ± 1.99 n.s.
15 min 79.83 ± 3.97 93.59 ± 10.71 n.s.
30 min 76.57 ± 7.04 97.45 ± 12.48 n.s.
60 min 77.85 ± 10.26 76.47 ± 7.84 n.s.
90 min 70.68 ± 3.31 72.23 ± 6.33 n.s.
120 min 68.34 ± 4.09 75.84 ± 4.38 n.s.
CORT (ng/mL)
0 min 251.32 ± 46.05 416.44 ± 93.29 n.s.
15 min 597.9 ± 41.26 756.44 ± 95.47 n.s
30 min 668.63 ± 46.18 1001.85 ± 132.73 0.05*
60 min 657.09 ± 65.02 980.83 ± 151.58 0.05*
90 min 744.51 ± 82.48 754.73 ± 129.68 n.s
120 min 537.63 ± 44.23 873.56 ± 158.80 n.s.
Values are mean ± SE. n.s. = non significant.
*t test.Reproductive Biology and Endocrinology 2005, 3:44 http://www.rbej.com/content/3/1/44
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PCO Rats Gain Less Total Body Weight
From weeks 3 to 10, PCO rats weighed less than controls,
but the difference was significant only between weeks 3
and 6 (Table 1). Overall, the PCO group gained signifi-
cantly less weight than the controls.
No Differences in Intraabdominal Fat Depots or Hindlimb 
Skeletal Muscles
The inguinal fat depot (representing subcutaneous fat),
was significantly heavier in the PCO group than in the
controls (4.36 ± 0.2 and 3.36 ± 0.2 g/kg body weight, P <
0.01). No differences were observed in the weights of the
mesenteric, parametrial, and retroperitoneal fat depots
(representing intraabdominal fat) or the hind limb skele-
tal muscles (not shown).
Discussion
This study shows that rats with EV-induced PCO devel-
oped hypertension, consistent with increased sympathetic
activity, as in human PCOS. They also had increased
expression of α1a AR mRNA in PVN and decreased expres-
sion of α2a  AR mRNA in PVN and adrenal medulla,
consistent with elevated blood pressure and increased
sympathetic activity, together with hyperactivity of the
HPA and SAM axes. Rats with EV-induced PCO did not
have reduced insulin sensitivity or become obese or
hyperandrogenic.
Sympathetic Activity and the SAM Axis
Women with PCOS have a high incidence of hypertension
[3,4] and are at increased risk of CVD [32]. The sympa-
thetic nervous system might play a crucial role in the
development of hypertension and CVD. As an example,
hypertension is common in patients with polycystic kid-
ney disease (PKD) and a recent study by Klein et al. dem-
onstrates that their muscle sympathetic nerve activity is
increased regardless of renal function [11]. This support
the hypothesis that sympathetic hyperactivity also may
contribute to the pathogenesis of hypertension in PCOS.
In addition, overactivity of the SAM axis increases blood
pressure [9]. Since sympathetic activity and hypertension
are strongly correlated, we measured MSAP and found
that it was increased at 5 and 7 weeks after EV injection.
This finding may have implications for the mechanisms
underlying the increased risk of developing hypertension,
including the higher incidence of CVD later in life, in
women with PCOS.
In the PCO group, α1a AR mRNA expression was increased
in the PVN, and α2a AR expression was reduced both in the
PVN and adrenal medulla, strongly suggesting increased
sympathetic activity. In spontaneously hypertensive rats,
increased central α1a AR expression and decreased α2a AR
expression correlated with elevated blood pressure and
increased sympathetic activity [15]. In another study,
Peng et al. showed that the α2a AR has a sympathoinhibi-
tory role in the brain [33]. Furthermore, α2 AR subtypes
have been demonstrated to control the release of catecho-
lamines from sympathetic nerves and from adrenal
medulla [34]. Since the hypothalamus participates in cen-
tral regulation of MSAP and adrenal medulla is involved
in the regulation of SAM-axis, these findings support the
conclusion that EV-induced PCO is associated with
increased sympathetic activity.
The PCO rats gained significantly less weight than con-
trols. The findings of enhanced adrenal glucocorticoid
production following EV-injection in the present study
might explain the lack of weight gain in PCO rats via lipo-
lytic actions. Activation of the α1  and  α2  ARs in the
hypothalamic paraventricular nucleus inhibits food
intake [35], suggesting that the dysregulated central
expression of α1 and α2 ARs in the PCO group was respon-
sible for the difference in weight gain. Food intake was not
measured. It is important to keep in mind that PCOS in
women is not always associated with obesity [36]. How-
ever, increased sympathetic nervous activity has been
associated with increased metabolic activity, fat
consumption, and decreased body weight, but not with
reduced food intake [37].
In a study of cardiovascular risk factors, young women
with PCOS had a higher prevalence of hypertension than
population controls [5] and a compromised cardiovascu-
lar risk profile, even after adjustment for their higher BMI.
In a recent study, low birth size and final height predicted
high sympathetic nerve activity in adulthood [38] and this
was positively correlated to high MSAP. Interestingly, low
Table 3: Estradiol, Testosterone, and Progesterone Concentrations 7 Weeks after EV Injection
Hormone Control group PCO group P
17β-estradiol (pmol/L) 0.23 ± 0.02 0.22 ± 0.03 n.s.
Testosterone (nmol/L) 0.45 ± 0.04 0.27 ± 0.02 0.01
Progesterone (nmol/L) 12.78 ± 1.10 22.54 ± 3.38 0.05
Values are mean ± SE. n.s. = not significant.Reproductive Biology and Endocrinology 2005, 3:44 http://www.rbej.com/content/3/1/44
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birth weight has been pointed out as an increased risk of
developing PCOS [39]. Thus, the increased CVD risk asso-
ciated with PCOS cannot be explained by obesity alone.
These findings suggest that the greater risk reflects
increased sympathetic nerve activity, which in turn results
in hypertension.
Signs of hyperactivation in EV-induced PCO include
downregulation of β2 AR in theca-interstitial cells [40].
Reduced expression of the β2 AR also enhances progester-
one secretion by cystic ovaries in response to isoprotere-
nol in rats with EV-induced PCO [19]. In the current
study, the PCO group had significantly higher progester-
one concentrations than the controls. In addition, high
levels of P and low levels of T suggest a metabolic shift
towards corticosterone synthesis and secretion and a
hyper-adrenal state.
All these changes seemed to be independent of 17β-estra-
diol, since they occurred without any changes in its con-
centrations [41]. Consistent with this finding, 17β-
estradiol concentrations were unaltered in the PCO
group.
Interactions Between the SAM and HPA Axes
The novel-environment stress test also provided evidence
for increased activity of the HPA axis in EV-induced PCO.
The PCO group had higher CORT levels at 30 and 60 min-
utes than controls. Corticotropin-releasing homone
(CRH) and locus ceruleus – NE (sympathetic nervous sys-
tem) have been pointed out as important components of
the stress system as well as their peripheral effectors, the
HPA and SAM axes [42]. The CRH and locus ceruleus – NE
systems directly modulate the HPA and SAM axes in order
to maintain homeostasis [42]. Rats with EV-induced PCO
have higher CRH levels in the median eminence than con-
trols [43]. In the present study, the development of hyper-
tension, increased expression of α1a AR and decreased
expression of α2a-AR mRNA, and increased CORT
responses to stress indicate a close interaction between the
HPA and SAM axes, as well as increases in their activity.
The interesting finding that the CORT response to stress
was higher whereas the ACTH response was lower then
expected can be explained by direct stimulation of adrenal
glucocorticoids with less pituitary ACTH action [44].
Insulin Resistance, Hyperandrogenism, and Obesity
According to one theory of the pathogenesis of PCOS, a
defect in insulin action leads to hyperinsulinemia and
insulin resistance [45]. The insulin clamp tests performed
10 to 11 weeks after EV injection, when typical PCO are
fully developed [17], showed no insulin resistance in the
PCO group.
Why didn't our rats with EV-induced PCO develop insulin
resistance? One possibility is that the measurements was
done prior to the onset of insulin resistance. Another pos-
sibility is absence of intraabdominal obesity, thought to
be a contributing factor [1]. The major abnormality in
insulin action in PCOS is believed to be a post-receptor
defect in the insulin signaling cascade in skeletal muscle,
which might be due to interaction with testosterone [1].
In humans, fasting insulin levels correlate positively with
androgen levels, and some studies have shown that hyper-
androgenism causes insulin resistance in humans [46]
and in rats [30]. Plasma testosterone levels were low in the
PCO group, consistent with the lack of insulin resistance
or hyperinsulinemia. As mentioned before, low levels of T
suggest a metabolic shift towards corticosterone synthesis
and secretion and a hyper-adrenal state.
It is also important to remember that only about 50% of
women with PCOS have insulin resistance and no more
than about 40% are obese [47]. Moreover, there are pit-
Table 4: Glucose Infusion Rate and Plasma Insulin and Glucose Concentrations before and at Steady State during the Euglycemic 
Hyperinsulinemic Clamp Test
Measurement Oil group PCO group P
Glucose infusion rate (mg/kg/min)* 26.6 ± 1.0 26.3 ± 1.1 n.s.
Glucose level (mmol/L)
0 min 6.5 ± 0.2 6.3 ± 0.2 n.s.
120 min 6.8 ± 0.1 6.7 ± 0.1 n.s.
Insulin level (mU/mL)
0 min 85 ± 17 69 ± 10 n.s.
120 min 280 ± 38 274 ± 66 n.s.
Values are mean ± SE. n.s. = not significant (t test).
*At steady state (60–120 min).Reproductive Biology and Endocrinology 2005, 3:44 http://www.rbej.com/content/3/1/44
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falls in assessing insulin resistance in PCOS, including the
lack of consensus on what defines PCOS and "normal"
insulin sensitivity, ethnic and genetic variability, con-
founding factors such as obesity, stress, and aging, and
concerns about whether simplified models of insulin sen-
sitivity have the precision to predict treatment needs,
responses, and morbidity [48].
Perspectives
Different models of PCO are inevitable, and the model to
use depends on the goals of the study. We demonstrated
that rats with EV-induced PCO develop hypertension,
with increased α1a AR and decreased α2a AR mRNA expres-
sion, consistent with increased sympathetic activity. We
also found evidence of increased HPA-axis activity.
These findings may have implications for mechanisms
underlying hypertension in women with PCOS, since
essential hypertension is associated with sympathetic
hyperactivity, which is itself known to increase CVD risk.
We also demonstrated that rats with EV-induced PCO do
not have reduced insulin sensitivity and do not develop
obesity or hyperandrogenism, which might be later signs
of sympathetic hyperactivity. Hyperglycemia of diabetic
PCOS patients has been found to be significantly posi-
tively correlated with adrenal hypersecretion of cortisol,
dehydroepiandrostenedione (DHEA) and
dehydroepiandrostenedione sulfate (DHEAS) [49]. They
suggested that enhanced adrenocortical (HPA) activity
may be important factor underlying the development of
type 2 diabetes in women with PCOS. Since we found
exaggerated activity in both HPA and SAM axes in the
PCO group control group 60 days after EV injection Figure 3
PCO group control group 60 days after EV injection. Survey view showing atretic follicles (1), regressing old corpora lutea (2), 
growing "healthy" follicles (3), and atretic secondary follicle with detachment of the oocyte from the cumulus mass of pycnotic 
granulosa cells (4) ×4 obj.
x4
11
1
1 2
2
2 4
3
3
2Reproductive Biology and Endocrinology 2005, 3:44 http://www.rbej.com/content/3/1/44
Page 9 of 10
(page number not for citation purposes)
present EV-induced PCO model, it might mimic an initial
stage of PCOS.
These findings might provide important leads for future
studies with the EV-induced PCO model.
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